Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor class drugs

11 results

  • Biktarvy

    (bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate)
    Gilead Sciences, Inc.
    Usage: BIKTARVY is indicated for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 14 kg, either as a complete regimen for those with no antiretroviral treatment history or as a replacement for those who are virologically suppressed on a stable regimen without resistance issues.

  • Complera

    (emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate)
    Gilead Sciences, Inc.
    Usage: COMPLERA® is indicated for treating HIV-1 in adults and children (≥35 kg) as initial therapy for those with no treatment history and HIV-1 RNA ≤100,000 copies/mL, or to replace a stable regimen in virologically suppressed patients. Limitations include risk of virologic failure in those with higher baseline HIV-1 RNA.

  • Delstrigo

    (doravirine, lamivudine, and tenofovir disoproxil fumarate)
    Merck Sharp & Dohme LLC
    Usage: DELSTRIGO® is indicated for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg, either as a complete regimen for those with no prior antiretroviral treatment or to replace the current regimen in patients who are virologically suppressed with no history of treatment failure.

  • Descovy

    (emtricitabine and tenofovir alafenamide)
    Gilead Sciences, Inc.
    Usage: DESCOVY is indicated for the treatment of HIV-1 infection in adults and pediatric patients (≥35 kg) in combination with other antiretroviral agents. It is also approved for HIV-1 pre-exposure prophylaxis (PrEP) in at-risk adults and adolescents (≥35 kg), excluding those at risk from receptive vaginal sex.

  • Dovato

    (dolutegravir sodium and lamivudine)
    ViiV Healthcare Company
    Usage: DOVATO is indicated for the treatment of HIV-1 infection in adults and adolescents (12 years and older, weighing at least 25 kg) who are either treatment-naive or virologically suppressed on a stable regimen without known resistance issues.

  • Genvoya

    (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide)
    Gilead Sciences, Inc.
    Usage: GENVOYA is indicated for the treatment of HIV-1 infection in adults and pediatric patients (≥25 kg) with no prior antiretroviral treatment history or to replace an existing regimen in virologically-suppressed patients on a stable regimen for at least six months without treatment failures or resistance.

  • Odefsey

    (emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide)
    Gilead Sciences, Inc.
    Usage: ODEFSEY is indicated for the treatment of HIV-1 infection in adults and pediatric patients (≥35 kg) as initial therapy for those with no prior treatment and HIV-1 RNA ≤100,000 copies/mL, or to replace a stable regimen in virologically-suppressed patients with specific criteria.

  • Stribild

    (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate)
    Gilead Sciences, Inc.
    Usage: STRIBILD® is indicated for treating HIV-1 in adults and pediatric patients aged 12 and older (weighing at least 35 kg) without prior antiretroviral treatment or to replace a stable regimen in those virologically suppressed for at least 6 months, without resistance to its components.

  • Symtuza

    (Darunavir, Cobicistat, Emtricitabine, and Tenofovir alafenamide)
    Janssen Products LP
    Usage: SYMTUZA is indicated for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 40 kg, either as a complete regimen for those with no prior antiretroviral treatment history or for those who are virologically suppressed on a stable regimen for at least 6 months.

  • Triumeq

    (abacavir sulfate, dolutegravir sodium, lamivudine)
    ViiV Healthcare Company
    Usage: TRIUMEQ and TRIUMEQ PD are indicated for the treatment of HIV-1 infection in adults and pediatric patients aged at least 3 months and weighing at least 6 kg. They are not recommended for patients with integrase resistance or suspected INSTI resistance due to insufficient dolutegravir dosage.